| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28a89f8dab024e02ae765d1273e716f1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91142
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate |
2019-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c732439670f2d7d5a9b21d91f05f661a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce3c48f405df4aa3894562f7ba2f4e5d |
| publicationDate |
2020-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020120410-A1 |
| titleOfInvention |
Methods of cancer treatment |
| abstract |
This invention relates to the finding that inhibition or inactivation of FAMIN ('fatty acid metabolism– immunity nexus'; C13orf31; LACC1 (laccase domain containing 1))reduces tumourigenesis and stimulates cell-mediated immune responses. Method of treating cancer orstimulating cell-mediated immune responsesin an individual byreducing FAMIN activity in the individual are provided. Also provided are methodsofactivating T cells in vitro using FAMIN deficient immune cells and stimulating cell-mediated immune responses comprising administering(a) a population of FAMIN deficient immune cells; or(b) a population of T cells activated in vitro by a population of FAMIN deficient immune cells. |
| priorityDate |
2018-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |